Comparison of Sirolimus and Everolimus Drug-eluting Stents for Treating the Patients With Non ST-elevation Acute Coronary Syndrome
10.3969/j.issn.1000-3614.2016.05.005
- VernacularTitle:西罗莫司与依维莫司药物洗脱支架治疗非ST段抬高型急性冠状动脉综合征的疗效比较
- Author:
Nana ZHANG
;
Guanghe WEI
;
Shaohui ZHANG
;
Lixin LIU
;
Jianjun WANG
;
Guoliang YANG
;
Ronghua GAO
;
Wen DAI
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Drug eluting stents;
Sirolimus;
Everolimus
- From:
Chinese Circulation Journal
2016;31(5):437-441
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the efifcacy and safety of sirolimus-eluting stent (SES) and everolimus-eluting stent (EES) for treating the patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS). Methods: A total of 400 NSTE-ACS patients treated in Jining Medical College Hospital from 2013-09 to 2014-09 were studied. According to different stents, the patients were divided into 2 groups: SES group,n=220 and EES group,n=180. A prospective follow-up study was conducted for 1.5 years to compare the incidence rate of major adverse cardiovascular events (MACE). The patients were further stratiifed by GRACE scores as Low risk group (score<109), Medium risk group (score 109-140) and High risk group (score>140). MACE free survival was studied by Kaplan-Meier curve and analyzed by Long-rank test, predictive value of GRACE for 1.5 year MACE incidence rate was examined. Results: There were 355/400 (89%) patients completed (16.7 ± 5.7) months of follow-up study including 205 in SES group and 150 in EES group. MACE occurrence rates were similar between SES group and EES group (16.10% vs 18.0%), P>0.05. By GRACE score stratiifcation, MACE rates in High risk SES group were higher than High risk EES group (48.00%vs 16.00%),P<0.05; while they were similar between Medium risk groups (14.49% vs 28.00%) and Low risk groups (9.11% vs 12.86%), allP>0.05. ROC curve indicated that the predictive value of GRACE score for 1.5 year MACE incidence was for AUC=0.762, 95% CI (1.026-1.050),P<0.001. Conclusion: Implanting of EES would be more beneifcial for NSTE-ACS patients with high GRACE risk; GRACE score has the better predictive value for their long-term prognosis.
